Comparable stake leader
Richard A. Kayne
SEC ownership of Eiger BioPharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001305253.
Disclosed value leader
Richard A. Kayne
Comparable rows
0/16
Latest evidence
31 Oct 2023
- Parsed ownership sources
- 3/4/5
- Largest SEC-reported holder
- Richard A. Kayne
- Latest parsed ownership date
- 31 Oct 2023
- Issuer CIK
- 0001305253
- Issuer location
- Palo Alto, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Eiger BioPharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Richard A. Kayne
Disclosed value leader
Richard A. Kayne
Comparable rows
0/16
Latest evidence
31 Oct 2023
3/4/5
Highest disclosed value: $1,600,204
16 rows are not safely comparable across share classes.
Showing 1-8 of 16 holder rows.
Quick read
Richard A. Kayne has the largest disclosed position value at $1.6M.
0 of 16 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Richard A. Kayne's linked filing trail.
Disclosed position value
Top 5
Richard A. Kayne
$1.6M
Leen Kawas
$1.31M
David A. Cory
$50.4K
Eldon C. Mayer III
$16.7K
Sriram Ryali
$12.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 16 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Richard A. Kayne |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,600,204
5,375,225 shares
|
— | 31 Oct 2023 |
| Leen Kawas |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,307,329
4,391,432 shares
|
— | 31 Oct 2023 |
| David A. Cory |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$50,366
450,183 shares
mixed-class rows
|
— | 11 Mar 2022 |
| Eldon C. Mayer III |
3/4/5
Ex VP & Chief Commerc. Officer
|
—
mixed-class rows
|
$16,693
154,073 shares
mixed-class rows
|
— | 17 Mar 2023 |
| Sriram Ryali |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$12,374
184,566 shares
mixed-class rows
|
— | 14 Mar 2022 |
| Ingrid Choong |
3/4/5
Chief Business Officer
|
—
mixed-class rows
|
$9,972
87,500 shares
mixed-class rows
|
— | 31 Aug 2023 |
| David Apelian |
3/4/5
CEO, Director
|
—
class O/S missing
|
—
750,000 shares
|
— | 03 Jul 2023 |
| James Vollins |
3/4/5
General Counsel
|
—
class O/S missing
|
—
120,000 shares
|
— | 30 Apr 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Eiger BioPharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Richard A. Kayne
Net 12M change
$0
Latest report
31 Oct 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Richard A. Kayne | 10%+ Owner | $1,600,204 | Filing P/S | 31 Oct 2023 | ||
| Leen Kawas | 10%+ Owner | $1,307,329 | Mixed | 31 Oct 2023 | ||
| David A. Cory | President and CEO, Director | $50,366 | Mixed | 11 Mar 2022 | ||
| Eldon C. Mayer III | Ex VP & Chief Commerc. Officer | $16,693 | Mixed | 17 Mar 2023 | ||
| Sriram Ryali | Chief Financial Officer | $12,374 | Mixed | 14 Mar 2022 | ||
| Ingrid Choong | Chief Business Officer | $9,972 | Mixed | 31 Aug 2023 | ||
| William G. Kachioff | Cfo | Mixed | 12 Apr 2023 | |||
| Thomas John Dietz | Director | Mixed | 01 Mar 2023 | |||
| Evan Loh | Director | Mixed | 01 Mar 2023 | |||
| Erik Atkisson | GC & Chief Compliance Officer | Mixed | 26 Jan 2023 | |||
| David Apelian | CEO, Director | Mixed | 03 Jul 2023 | |||
| Jeffrey S. Glenn | Director | Mixed | 01 Mar 2023 | |||
| Kim Sablich | Director | Mixed | 01 Mar 2023 | |||
| Lisa Kelly-Croswell | Director | Mixed | 01 Mar 2023 | |||
| James Vollins | General Counsel | Mixed | 30 Apr 2023 | |||
| Christine Murray | Director | Mixed | 01 Mar 2023 | |||
| Amit Sachdev | Director | Mixed | 01 Mar 2023 |
Recent insider transactions for Eiger BioPharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.